Skip to main content
Top
Published in: International Journal of Clinical Oncology 2/2011

01-04-2011 | Original Article

Expression of thrombospondin-1 and Ski are prognostic factors in advanced gastric cancer

Authors: Toshihiro Nakao, Nobuhiro Kurita, Masato Komatsu, Kozo Yoshikawa, Takashi Iwata, Toru Utsunomiya, Mitsuo Shimada

Published in: International Journal of Clinical Oncology | Issue 2/2011

Login to get access

Abstract

Background

It has been suggested that thrombospondin-1 (TSP-1) plays a role in angiogenesis in many cancers. In addition, TSP-1 has been shown to suppress tumor growth by activating transforming growth factor-β (TGF-β). Recent studies have shown that Ski protein suppresses TGF-β signaling. The aim of this study was to investigate the role of TSP-1 and Ski expression in advanced gastric cancer.

Methods

Sixty-five recurrent patients who underwent resection of advanced gastric cancer (n = 62) or who had unresectable tumors (n = 3) between March 2003 and October 2007 participated in this study. All patients were treated with chemotherapy after collection of the tumor tissue. Twenty-three of them were also treated with chemotherapy before collection of the tumor specimen. The TSP-1, Ski, vascular endothelial growth factor (VEGF) and TGF-β protein expression were examined by immunohistochemical staining, and microvessels in the tumor were counted.

Results

There were 17 (26.2%) gastric cancers with positive staining for TSP-1. There was no relationship between TSP-1 expression and clinicopathological factors.
TSP-1 expression had positive association with VEGF expression, microvessel density (MVD) and TGF-β expression. However, there was no relationship between TSP-1 and Ski expression. TSP-1 correlated with good survival in advanced gastric cancer, and Ski correlated with poor survival in the patients with TGF-β-positive advanced gastric cancer.

Conclusions

This study shows that TSP-1 enhances angiogenesis due to its positive correlation with VEGF and MVD, and is a good prognostic factor for survival in advanced gastric cancer. This study also shows that Ski inhibits the prolonged effects of TGF-β for survival in advanced gastric cancer.
Literature
2.
go back to reference Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108PubMedCrossRef Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108PubMedCrossRef
3.
go back to reference Ganguly P (1971) Isolation and properties of a thrombin-sensitive protein from human blood platelets. J Biol Chem 246(13):4286–4290PubMed Ganguly P (1971) Isolation and properties of a thrombin-sensitive protein from human blood platelets. J Biol Chem 246(13):4286–4290PubMed
4.
go back to reference Maeda K, Nishiguchi Y, Kang SM et al (2001) Expression of thrombospondin-1 inversely correlated with tumor vascularity and hematogenous metastasis in colon cancer. Oncol Rep 8(4):763–766PubMed Maeda K, Nishiguchi Y, Kang SM et al (2001) Expression of thrombospondin-1 inversely correlated with tumor vascularity and hematogenous metastasis in colon cancer. Oncol Rep 8(4):763–766PubMed
5.
go back to reference Yamaguchi M, Sugio K, Ondo K et al (2002) Reduced expression of thrombospondin-1 correlates with a poor prognosis in patients with non-small cell lung cancer. Lung Cancer 36(2):143–150PubMedCrossRef Yamaguchi M, Sugio K, Ondo K et al (2002) Reduced expression of thrombospondin-1 correlates with a poor prognosis in patients with non-small cell lung cancer. Lung Cancer 36(2):143–150PubMedCrossRef
6.
go back to reference Grossfeld GD, Ginsberg DA, Stein JP et al (1997) Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst 89(3):219–227PubMedCrossRef Grossfeld GD, Ginsberg DA, Stein JP et al (1997) Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst 89(3):219–227PubMedCrossRef
7.
go back to reference Morelli D, Lazzerini D, Cazzaniga S et al (1998) Evaluation of the balance between angiogenic and antiangiogenic circulating factors in patients with breast and gastrointestinal cancers. Clin Cancer Res 4(5):1221–1225PubMed Morelli D, Lazzerini D, Cazzaniga S et al (1998) Evaluation of the balance between angiogenic and antiangiogenic circulating factors in patients with breast and gastrointestinal cancers. Clin Cancer Res 4(5):1221–1225PubMed
8.
go back to reference Kasper HU, Ebert M, Malfertheiner P et al (2001) Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density. Virchows Arch 438:116–120PubMedCrossRef Kasper HU, Ebert M, Malfertheiner P et al (2001) Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density. Virchows Arch 438:116–120PubMedCrossRef
9.
go back to reference Yamashita Y, Kurohiji T, Tuszynski GP et al (1998) Plasma thrombospondin levels in patients with colorectal carcinoma. Cancer 82:632–638PubMedCrossRef Yamashita Y, Kurohiji T, Tuszynski GP et al (1998) Plasma thrombospondin levels in patients with colorectal carcinoma. Cancer 82:632–638PubMedCrossRef
10.
go back to reference Heldin CH, Miyazono K, ten Dijke P (1997) TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 390:465–471PubMedCrossRef Heldin CH, Miyazono K, ten Dijke P (1997) TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 390:465–471PubMedCrossRef
11.
go back to reference Maeda K, Nishiguchi Y, Yashiro M et al (2000) Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma. Int J Mol Med 5:373–378PubMed Maeda K, Nishiguchi Y, Yashiro M et al (2000) Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma. Int J Mol Med 5:373–378PubMed
12.
go back to reference Poon RT, Chung KK, Cheung ST et al (2004) Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma. Clin Cancer Res 10:4150–4157PubMedCrossRef Poon RT, Chung KK, Cheung ST et al (2004) Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma. Clin Cancer Res 10:4150–4157PubMedCrossRef
13.
go back to reference Pratt DA, Miller WR, Dawes J (1989) Thrombospondin in malignant and non-malignant breast tissue. Eur J Cancer Clin Oncol 25:343–350PubMedCrossRef Pratt DA, Miller WR, Dawes J (1989) Thrombospondin in malignant and non-malignant breast tissue. Eur J Cancer Clin Oncol 25:343–350PubMedCrossRef
14.
go back to reference Luo Ski K, Sno N (2004) Negative regulators of TGF-beta signaling. Curr Opin Genet Dev 14:65–70CrossRef Luo Ski K, Sno N (2004) Negative regulators of TGF-beta signaling. Curr Opin Genet Dev 14:65–70CrossRef
15.
go back to reference Zhang J, Ito R, Oue N et al (2003) Expression of thrombospondin-1 is correlated with microvessel density in gastric carcinoma. Virchows Arch 442:563–568PubMed Zhang J, Ito R, Oue N et al (2003) Expression of thrombospondin-1 is correlated with microvessel density in gastric carcinoma. Virchows Arch 442:563–568PubMed
16.
go back to reference Takahata M, Inoue Y, Tsuda H et al (2009) SKI and MEL1 cooperate to inhibit transforming growth factor-beta signal in gastric cancer cells. J Biol Chem 284:3334–3344PubMedCrossRef Takahata M, Inoue Y, Tsuda H et al (2009) SKI and MEL1 cooperate to inhibit transforming growth factor-beta signal in gastric cancer cells. J Biol Chem 284:3334–3344PubMedCrossRef
17.
go back to reference Saito H, Tsujitani S, Ikeguchi M et al (1998) Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue. Br J Cancer 78:1573–1577PubMedCrossRef Saito H, Tsujitani S, Ikeguchi M et al (1998) Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue. Br J Cancer 78:1573–1577PubMedCrossRef
18.
go back to reference Saito H, Tsujitani S, Oka S et al (1999) The expression of transforming growth factor-beta1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer 86:1455–1462PubMedCrossRef Saito H, Tsujitani S, Oka S et al (1999) The expression of transforming growth factor-beta1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer 86:1455–1462PubMedCrossRef
19.
go back to reference Vermeulen PB, Gasparini G, Fox SB et al (1996) Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 32A:2474–2484PubMedCrossRef Vermeulen PB, Gasparini G, Fox SB et al (1996) Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 32A:2474–2484PubMedCrossRef
20.
go back to reference Fondevila C, Metges JP, Fuster J et al (2004) p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer 90:206–215PubMedCrossRef Fondevila C, Metges JP, Fuster J et al (2004) p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer 90:206–215PubMedCrossRef
21.
go back to reference Greenaway J, Lawler J, Moorehead R et al (2007) Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1). J Cell Physiol 210:807–818PubMedCrossRef Greenaway J, Lawler J, Moorehead R et al (2007) Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1). J Cell Physiol 210:807–818PubMedCrossRef
22.
go back to reference Poon RT, Chung KK, Cheung ST et al (2004) Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma. Clin Cancer Res 10:4150–4157PubMedCrossRef Poon RT, Chung KK, Cheung ST et al (2004) Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma. Clin Cancer Res 10:4150–4157PubMedCrossRef
23.
go back to reference Hironaka S, Hasebe T, Kamijo T et al (2002) Biopsy specimen microvessel density is a useful prognostic marker in patients with T(2–4)M(0) esophageal cancer treated with chemoradiotherapy. Clin Cancer Res 8:124–130PubMed Hironaka S, Hasebe T, Kamijo T et al (2002) Biopsy specimen microvessel density is a useful prognostic marker in patients with T(2–4)M(0) esophageal cancer treated with chemoradiotherapy. Clin Cancer Res 8:124–130PubMed
24.
go back to reference Kiyono K, Suzuki HI, Morishita Y et al (2009) c-Ski overexpression promotes tumor growth and angiogenesis through inhibition of transforming growth factor-beta signaling in diffuse-type gastric carcinoma. Cancer Sci 100:1809–1816PubMedCrossRef Kiyono K, Suzuki HI, Morishita Y et al (2009) c-Ski overexpression promotes tumor growth and angiogenesis through inhibition of transforming growth factor-beta signaling in diffuse-type gastric carcinoma. Cancer Sci 100:1809–1816PubMedCrossRef
Metadata
Title
Expression of thrombospondin-1 and Ski are prognostic factors in advanced gastric cancer
Authors
Toshihiro Nakao
Nobuhiro Kurita
Masato Komatsu
Kozo Yoshikawa
Takashi Iwata
Toru Utsunomiya
Mitsuo Shimada
Publication date
01-04-2011
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 2/2011
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-010-0147-5

Other articles of this Issue 2/2011

International Journal of Clinical Oncology 2/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine